Seeking Broad Intervention In India, Eli Lilly Goes To Roots To Check Non-communicable Diseases

MUMBAI - Following the Indian government's heightened concerns over a sharply increased prevalence rate of non-communicable diseases such as diabetes and cancer, Eli Lilly & Co. has allocated $8-9 million to analyze the disease burden in India and devise intervention strategies based on the data

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip